Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 50% ± 14% | |
lung | 18 studies | 45% ± 15% | |
intestine | 9 studies | 31% ± 13% | |
kidney | 7 studies | 36% ± 13% | |
lymph node | 7 studies | 35% ± 19% | |
liver | 7 studies | 29% ± 10% | |
placenta | 5 studies | 50% ± 29% | |
uterus | 5 studies | 52% ± 17% | |
bone marrow | 4 studies | 36% ± 15% | |
skin | 4 studies | 26% ± 11% | |
breast | 4 studies | 44% ± 9% | |
adrenal gland | 3 studies | 37% ± 12% | |
prostate | 3 studies | 37% ± 12% | |
brain | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 9396.79 | 180 / 180 | 100% | 1605.51 | 428 / 430 |
skin | 100% | 8576.49 | 1806 / 1809 | 95% | 775.58 | 450 / 472 |
uterus | 100% | 8558.52 | 170 / 170 | 93% | 564.51 | 428 / 459 |
lung | 100% | 11470.24 | 578 / 578 | 93% | 465.42 | 1073 / 1155 |
breast | 100% | 10596.77 | 459 / 459 | 92% | 514.57 | 1031 / 1118 |
esophagus | 100% | 5916.64 | 1444 / 1445 | 92% | 416.26 | 168 / 183 |
thymus | 100% | 4966.59 | 650 / 653 | 78% | 267.70 | 473 / 605 |
bladder | 100% | 5200.24 | 21 / 21 | 77% | 421.14 | 389 / 504 |
kidney | 100% | 9927.29 | 89 / 89 | 69% | 241.45 | 625 / 901 |
intestine | 92% | 3545.07 | 892 / 966 | 72% | 269.41 | 382 / 527 |
adrenal gland | 100% | 11460.95 | 258 / 258 | 64% | 343.37 | 148 / 230 |
prostate | 100% | 7296.19 | 244 / 245 | 62% | 113.26 | 309 / 502 |
stomach | 79% | 2721.57 | 285 / 359 | 79% | 345.07 | 226 / 286 |
pancreas | 52% | 1219.66 | 169 / 328 | 92% | 563.13 | 164 / 178 |
liver | 100% | 15060.02 | 226 / 226 | 39% | 124.70 | 160 / 406 |
brain | 98% | 6928.21 | 2600 / 2642 | 33% | 58.30 | 231 / 705 |
spleen | 100% | 10363.80 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 566.74 | 45 / 45 |
adipose | 100% | 8857.79 | 1202 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 698.84 | 79 / 80 |
heart | 97% | 3444.36 | 831 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 92% | 4274.74 | 1234 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 85% | 8874.92 | 793 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 72% | 180.26 | 21 / 29 |
muscle | 24% | 464.58 | 192 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0046597 | Biological process | negative regulation of viral entry into host cell |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0098552 | Cellular component | side of membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0030550 | Molecular function | acetylcholine receptor inhibitor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | LY6E |
Protein name | Lymphocyte antigen 6E (Ly-6E) (Retinoic acid-induced gene E protein) (RIG-E) (Stem cell antigen 2) (SCA-2) (Thymic shared antigen 1) (TSA-1) Lymphocyte antigen 6 family member E (Lymphocyte antigen 6E) |
Synonyms | TSA1 9804 RIGE SCA2 |
Description | FUNCTION: GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation (By similarity). Restricts the entry of human coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2, by interfering with spike protein-mediated membrane fusion . Also plays an essential role in placenta formation by acting as the main receptor for syncytin-A (SynA). Therefore, participates in the normal fusion of syncytiotrophoblast layer I (SynT-I) and in the proper morphogenesis of both fetal and maternal vasculatures within the placenta. May also act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity (By similarity). .; FUNCTION: (Microbial infection) Promotes entry, likely through an enhanced virus-cell fusion process, of various viruses including HIV-1, West Nile virus, dengue virus and Zika virus . In contrast, the paramyxovirus PIV5, which enters at the plasma membrane, does not require LY6E . Mechanistically, adopts a microtubule-like organization upon viral infection and enhances viral uncoating after endosomal escape . . |
Accessions | ENST00000520531.5 Q16553 ENST00000631568.1 ENST00000619718.2 ENST00000633934.1 E7EWF8 ENST00000633898.1 ENST00000292494.11 E5RI33 ENST00000522024.1 ENST00000632978.1 ENST00000522971.5 E5RIQ1 ENST00000521699.5 ENST00000632516.1 ENST00000521182.5 ENST00000632902.1 ENST00000429120.6 ENST00000523847.5 ENST00000521003.5 ENST00000632232.1 ENST00000517503.1 E5RGI6 ENST00000519546.5 ENST00000632618.1 ENST00000633451.1 ENST00000632519.1 ENST00000632812.1 ENST00000633551.1 ENST00000519611.5 ENST00000520466.5 ENST00000632424.1 ENST00000522528.5 E5RI58 |